SEC Tracker
Get the app

Possible new AEON Biopharma shares

AEONDilution

Known so far: no new shares from the prospectus covers read · shelf room about $2.9M · not yet read: warrants, converts, options, ATM.

Shelf room

  • Room today about $2.9M
  • One third of float $2.9M ($8.7M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $2.9M on the S-3 of Feb 9, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $8.7M public float stated as of Jun 30, 2025, $2.9M, nothing sold off it in the last 12 months. Sources: S-3 Feb 9, 2026, effective Feb 17, 2026 · public float, as of Jun 30, 2025.

What could become new AEON Biopharma (AEON) shares, from its 10-Q, 10-K, S-1 or 424B filings.

Read so far: the cover share count (49.9M shares, +4184% from 1.2M on Aug 8, 2025). Not read yet: warrants, convertible notes, options and RSUs and an ATM program. Read them on EDGAR: the latest 10-Q · S-1 registration filings.

Financing terms to know

None found in filings since Nov 3, 2026.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

49.9M

Nov 2024 to Aug 2026: from 1.1M to 49.9M. Adjusted for two reverse splits, about 1-for-4 by Mar 21, 2025 and about 1-for-10 by Aug 8, 2025: each earlier count is divided by the ratio of every split after it.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.